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ImmunologyGaucher disease (GD) is caused by reduced activity of the lysosomal enzyme glucocerebrosidase, which leads
to a buildup of glucocerebroside within the cells and chronic stimulation of the immune system. GD is asso-
ciated with clinical variability even in the same family, which suggests the inﬂuence of modiﬁer genes. Nat-
ural killer (NK) cells play an important role in the immune response, and their number is decreased in GD.
Killer-cell immunoglobulin-like receptors (KIR) regulate the activity of NK cells through an interaction
with speciﬁc human leukocyte antigen (HLA) class I molecules on target cells.
Objectives: To analyze the variability of KIR genes in a sample of GD patients from Southern Brazil, and look
for associations between variants and clinical manifestations.
Methodology: Thirty-one GD patients (24 mild, 4 moderate, and 3 severe) were included in the study. Fifteen
KIR genes, HLA-C and HLA-Bw4 were analyzed using SSP-PCR. Clinical, biochemical, and radiological data
were collected by means of a chart review.
Results/Discussion: Age at symptom onset was associated with KIR2DL2 and KIR2DS2 in combination with the
ligand HLA-C1 (p=0.038). Patients who have the HLA-C2 variant appear to have more mono- and polyclonal
bands on protein electrophoresis (p=0.007, OR 21.3). There was no between-group signiﬁcant difference in
the frequencies of KIR/HLA variants.
Conclusion: Although exploratory our data suggest a possible association of KIR/HLA variants and the severity
of GD. Further study of KIR/HLA variants is required, as they seem to be a phenotype-modifying factor in this
disease.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Gaucher disease (GD, OMIM 230800) is the most common lyso-
somal storage disorder, with an estimated worldwide incidence of 1
case per 57,000 live births (Meikle and Hopwood, 2003), although
this rate can reach 1 in 400 among Ashkenazi Jews (Sobreira et al.,
2007).Cs, Gaucher cells; GD, Gaucher
ll immunoglobulin-like recep-
d signiﬁcance; MM, multiple
arrow Donors Registry; SSI, se-
nts is required as they seem to
nt, Hospital de Clínicas de Porto
35-903, Brazil. Tel.: +55 51
vier OA license.GD is caused by mutations in both alleles of the GBA gene, which
codes for lysosomal glucocerebrosidase (EC 3.2.1.45), an enzyme re-
sponsible for catalyzing the hydrolysis of glucocerebroside into glucose
and ceramide (Beutler, 2006). Consequently, there is intracellular accu-
mulation of glucocerebroside inmacrophages, particularly in the spleen,
liver, bone marrow, and lungs. GD is therefore a multisystem disorder,
and exhibits phenotypic heterogeneity. Although the genetic changes
and biochemical pathways that underlie GD have been well character-
ized, the mechanisms whereby accumulation of glucocerebroside leads
to clinical manifestations have yet to be fully determined (Hughes and
Pastores, 2010; Jmoudiak and Futerman, 2005).
Gaucher cells (GCs, lipid-laden macrophage derivatives) have ec-
centric nuclei and cytoplasmic striations. Their expression of macro-
phage surface markers and marked phagocytic activity conﬁrm the
ontogeny of GCs asmononuclear phagocytes (Boven et al., 2004). In ad-
dition to lipid substrate buildup, the pathogenesis of GD can be
explained by defects in enzyme conformation and endoplasmic reticu-
lum stress (Ron and Horowitz, 2005), defects in calcium homeostasis
(one of the mechanisms responsible for the neuropathology seen in
54 F. Vairo et al. / Gene 516 (2013) 53–57patients with acute neuronopathic GD) (Pelled et al., 2005), increased
sensitivity to oxidative stress (Deganuto et al., 2007), and changes in
autophagy mechanisms (Sun and Grabowski, 2010). It has also been
speculated that changes in macrophage function may contribute to
some components of GD, particularly hepatosplenomegaly and bone in-
volvement (Mizukami et al., 2002).
One of the most widespread hypotheses to explain phenotypic
variation in GD is the presence of a chronic immune stimulus
(Shoenfeld et al., 1982). Patients with GD exhibit elevated levels of
IgA, IgG, and IgM, autoantibodies (Jurecka et al., 2011; Shoenfeld et
al., 1995), and increased incidence of polyclonal gammopathy, mono-
clonal gammopathy of undetermined signiﬁcance (MGUS), and mul-
tiple myeloma (MM) (de Fost et al., 2008; Hughes, 2009). This
immune response might generate an inﬂammatory response, leading
to cytokine-mediated cell damage. Some of the cytokines found at el-
evated levels in GD patients include IL-1, IL-6, IL-10, TNF-α, and
M-CSF (Barak et al., 1999; Hollak et al., 1997). As cytokines play an
important role in the regulation of immune system cells, some au-
thors ascribe their imbalance to a pro-inﬂammatory state and to the
onset of hematological malignancies (Brody et al., 2006; Costello et
al., 2006; Hawkesford et al., 2011; Rosenbloom et al., 2005). Another
evidence of a pro-inﬂammatory response in GD patients is the pres-
ence of elevated levels of antigen-presenting molecules, including
MHC class II antigens (HLA-DR) (Balreira et al., 2005; Florena et al.,
1996).
Natural killer (NK) cells are lymphocytes that can be distinguished
from T and B cells by their larger size and granular cytoplasm. NK cells
are a component of the innate immune system and play a role in the de-
fense against infectious pathogens and malignancy, exhibiting inﬂam-
matory cytokine-mediated cytotoxic and cytolytic effects (Leavy,
2012). NK cells express at least one inhibitory receptor that interacts
with HLA class I (HLAs A, B, and C) to exert an important controlling ef-
fect and prevent immune response from targeting healthy cells
(Moretta et al., 2004).
Killer cell immunoglobulin-like receptors (KIR) are members of the
immunoglobulin family found on the surface of NK cells (Moretta et al.,
1990) and some T lymphocytes (NKT) (Van Kaer, 2007). Thus far, 15
KIR genes (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B,
KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2,
KIR3DL3 e KIR3DS1) and two pseudogenes (KIR2DP1 and KIR3DP1)
have been described (Marsh et al., 2003), located on the 19q13.4 region
(Suto et al., 1996). KIR receptors are the result of a polymorphic system
and are divided into activating and inhibitory isoforms. Receptors that
mediate an inhibitory signal possess a long cytoplasmic tail (and are
thus denoted by the letter “L”) and prevent target cell lysis, whereas ac-
tivating KIRs possess a short tail (denoted by the letter “S”) and aid cell
lysis (Biassoni et al., 1996; Fan et al., 1997).
KIR genes have increasingly been associated with variability in re-
sponse to viral diseases (HIV, CMV, viral hepatitides) (Marangon et
al., 2011; Stern et al., 2008; Tiemessen et al., 2011) and with autoim-
mune diseases such as scleroderma, rheumatoid arthritis, and psoria-
sis (Jobim et al., 2008; Martin et al., 2003; Salim et al., 2010). Due to
the haplotype diversity of KIR genes, there is interest in analyzing
their potential association with other disease states. For instance, an
association between HLA ligands and KIR receptors has been impli-
cated in the development of preeclampsia (Hiby et al., 2004), hema-
tologic neoplasms (Karabon et al., 2011; Leung et al., 2007), and
solid tumors (Romagne et al., 2009). Therefore, as GD is associated
with intra-familial variability (Amaral et al., 1994) and it is also asso-
ciated with a reduction in NK cells (Burstein et al., 1987), with hema-
tological malignancies and with an increase in the levels of natural
autoantibodies (Shoenfeld et al., 1995), we may speculate that KIR/HLA
variants are phenotype modifying factor of GD.
This is an exploratory study which aimed to ascertain whether
correlations exist between KIR genes, their HLA ligands and clinical
features in a cohort of GD patients from Southern Brazil.2. Methods
2.1. Patients and controls
The study sample comprised 31 patients (from 28 unrelated fami-
lies) with a biochemical and molecular diagnosis of GD followed at the
State Reference Center for Gaucher disease of Rio Grande do Sul, Brazil,
from 2003 to 2011. Of these 31 patients, 28 were receiving enzyme re-
placement therapy (ERT) with imiglucerase (n=23) or taliglucerase
alfa (n=5) with a mean time of treatment of 97.21 months (range
4–215). All patients were European descendants, had been born in the
South region of Brazil, and denied Ashkenazi Jewish ancestry. Patients
(or the legal guardians of patients under the age of 18) providedwritten
informed consent for participation in the study, and clinical, biochemi-
cal, and radiological data were collected by means of a chart review.
The study was approved by the Hospital de Clínicas de Porto Alegre Re-
search Ethics Committee.
The following clinical parameters were assessed: age at onset of
symptoms (when available) or age at diagnosis; the highest GD se-
verity score index (SSI) (Zimran et al., 1992) presented for each pa-
tient during follow-up (use of this score was implemented at our
service in 2007; therefore, patients diagnosed in previous years have
no record of pretreatment SSI scores); presence of osteopenia or osteo-
porosis (as assessed by bone density scanning) or osteonecrosis (as di-
agnosed on plain radiographs) on at least one occasion; presence of
hyperimmunoglobulinemia on at least one occasion; and presence of
polyclonal or monoclonal bands on serum protein electrophoresis on
at least one occasion.
The frequencies of the variants were compared with the data
obtained from 250 healthy European descendants, bone marrow do-
nors from Rio Grande do Sul, Brazil, drawn from the National Bone
Marrow Donors Registry (REDOME) (Jobim et al., 2010).
2.2. KIR and HLA typing
Fifteen KIR genes (2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DS1, 2DL1, 2DL2,
2DL3, 2DL4, 2DL5, 3DL1, 3DL2, 3DL3 e 2DP1), HLA-C and HLA-Bw4
were analyzed using the PCR ampliﬁcation with sequence-speciﬁc
primers (SSP-PCR) technique as previously described (Bunce et al.,
1995). The results of HLA-C typing were separated into two groups:
HLA-C group 1 (C1), consisting of HLA-C 01, 03, 07 (01–06), 08, 12
(02, 03, 06), 14, 16 (01, 03, 04), and HLA-C group 2 (C2), consisting
of HLA-C 02, 04, 05, 06, 0707, 12 (04, 05), 15, 1602, 17, 18 (Jobim et
al., 2008). HLA-C group 1 (C1) molecules bind to KIR2DS2, KIR2DL2
and KIR2DL3, whereas group 2 (C2) molecules bind to KIR2DS1 and
KIR2DL1. Bw4 molecules bind to KIR3DL1 and KIR3DL1 (Biassoni et
al., 1995).
2.3. Statistical analysis
Pearson's chi-square test with continuity correction was used to
compare KIR gene and HLA-C frequencies between the GD and control
groups, and Bonferroni correction for multiple comparisons was
performed. In a few cases where the expected difference between
the two groups was small, Fisher's exact test was employed. There
was no adjustment for population stratiﬁcation. Odds ratios (OR),
conﬁdence intervals (95%CI), and p values (pb0.050) were calculated
using SPSS for Windows 16.0 (SPSS Inc., Chicago, IL).
3. Results
The clinical and demographic proﬁle of the study sample is shown
in Table 1.
There were no signiﬁcant differences between the GD and control
groups in frequency of KIR gene, HLA-C, and HLA-Bw4 variants
(Table 2). Frequencies were similar to those reported in previous
Table 1
Clinical and demographic features of the study sample.
Patients (n=31)
Gender (female:male ratio) 13:18
Mean age±SD (years) 29.48±15.19
Mean age at onset of
symptoms±SD (years)b
37.5±16.7
Disease severity (SSI)a Mild (0–10)c 24
Moderate (11–25)d 4
Severe (>25)e 3
Hyperimmunoglobulinemia 24
Monoclonal/Polyclonal bands on
protein electrophoresis
14
Osteopenia/Osteoporosis 18
Osteonecrosis 9
a According to Zimran et al. (1992). SD: standard deviation.
b When unavailable, age at diagnosis was used instead.
c Mean age±SD (years): 31±16.31.
d Mean age±SD (years): 30.25±8.01.
e Mean age±SD (years): 16.33±4.04.
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al., 2008). The frequency of KIR gene variants in combination with
their respective ligands was also determined and compared between
the GD and control groups; again, there were no signiﬁcant differ-
ences (Table 2).
Comparison of the frequencies of speciﬁc KIR gene variants in the GD
group and analysis of the potential association of these variantswith age
at diagnosis or symptom onset, presence of hyperimmunoglobulinemia,
presence of mono- or polyclonal bands on protein electrophoresis, and
osteoporosis or osteonecrosis revealed a signiﬁcant association (p=
0.038) between the absence of the KIR2DS2 and KIR2DL2/HLA-C1 com-
bination and symptom onset after childhood (16 out of 19 did not have
this combination, whereas 7 of the 12 patients in whom symptom onset
occurred at age >18 years did).
A signiﬁcant association was also found between HLA-C typing
and changes on serum protein electrophoresis. Patients who wereTable 2
KIR gene, ligand frequencies and their association in Gaucher disease (GD) patients
(n=31) and in controls (n=250).
KIR gene, ligands and association Controls GD p-Valuea
N % N %
2DL1 244 97.6 31 100.0 1.000
2DL2 136 54.4 15 48.4 0.549
2DL3 216 86.4 28 90.3 0.589
2DL4 250 100.0 31 100.0 1.000
2DL5 124 49.6 18 58.1 0.819
3DL1 244 97.6 31 100.0 1.000
3DL2 200 100.0 31 100 1.000
3DL3 200 100.0 31 100.0 1.000
2DS1 91 36.4 13 41.9 0.825
2DS2 134 53.6 14 45.2 0.407
2DS3 83 33.2 9 29.0 0.510
2DS4 238 95.2 31 100.0 0.612
2DP1 200 100.0 31 100.0 1.000
2DS5 85 34.0 16 51.6 0.084
3DS1 106 42.4 9 29.0 0.171
Bw4 179 71.6 22 71.0 1.000
C1 180 72.0 22 71.0 0.984
C2 179 71.6 24 77.4 0.403
2DL2/C1 102 40.8 10 32.3 0.432
2DS2/C1 100 40.0 10 32.3 0.340
2DL3/C1 153 61.2 20 64.5 0.778
2DL1/C2 176 70.4 24 77.4 0.499
2DS1/C2 63 25.2 10 32.3 0.565
3DL1/Bw4 174 69.6 22 71.0 1.000
3DS1/Bw4 77 30.8 4 12.9 0.075
C1 group: HLA-Cw 01, 03, 07 (01–06), 08, 12 (02, 03, 06), 14, 16 (01, 03, 04).
C2 group: HLA-Cw 02, 04, 05, 06, 0707, 12 (04, 05), 15, 1602, 17, 18.
a Bonferroni-adjusted alpha for signiﬁcance pb0.002.homozygous for group HLA-C2 had an OR=21.3 (95% CI: 2.18–208.7,
p=0.007) for the presence ofmonoclonal or polyclonal bands, whereas
patients with at least one C1 allele (C1/C1 or C1/C2 genotype) had an
OR=0.047 (95% CI: 0.005–0.459, p=0.004) for showing those ﬁndings
(Table 3).
No other signiﬁcant associations were found between other clini-
cal and demographic parameters and KIR gene frequencies.
4. Discussion
GD is the most prevalent lysosomal storage disorder, and that in
which immune system involvement plays the greatest role (Castaneda
et al., 2008). The main hypothesis is that a buildup of glucocerebroside
within macrophage lysosomes leads to persistent inﬂammatory stimu-
lation, but the exact mechanism is still unclear. Some of the features of
the characteristic immune involvement of GD include a blunted antigen
response to bacterial pathogens, which can improve with ERT (Marodi
et al., 1995); increased incidence of B cell-related malignancies, such
as lymphomas, leukemias, monoclonal gammopathies, and multiple
myeloma (Camou and Viallard, 2012; Hawkesford et al., 2011; Ranade
et al., 2010; Rosenbloom et al., 2009); and presence of autoantibodies
(Shoenfeld et al., 1995). As lysosomal accumulation of substrate occurs
in immune system cells, antigen presentation by HLA class I and class II
molecules is also compromised (Balreira et al., 2005), and, asmentioned
before, there is a decrease in the number of NK cells and impairment in
their activity (Burstein et al., 1987). NK cells are important components
of the innate immune system, as they are able to eliminate tumor cells
and virus-infected cells (Leavy, 2012). The role of NK cells in the patho-
physiology of and susceptibility to autoimmune disease has increasing-
ly been the object of research (Jobim et al., 2008; Qin et al., 2011; Salim
et al., 2010), due to the high allelic variability of NK cell receptors. It is
also widely known that GD is associated with intra-familial variability
(Amaral et al., 1994). All these factors together led us to believe that
immune-related factors, including theKIR gene variants,may be pheno-
type modiﬁers in GD.
Comparison of the frequencies of the 15 known KIR genes be-
tween the GD and control groups revealed no signiﬁcant differences.
This was expected, in view of the ethnic homogeneity of both groups,
or even because of the small size sample and the resulting insufﬁcient
statistical power. However, analysis of the potential associations be-
tween KIR variants and clinical, demographic, and laboratory param-
eters revealed some interesting data.
The KIR2DS2 or KIR2DL2/HLA-C1 combination appears to be associ-
atedwith delayed symptom onset, as it was present in only 15.8% of pa-
tients whose symptoms ﬁrst arose before the age of 18, whereas 58.3%
of patients with adult-onset symptoms have these combinations. It
bears stressing that the KIR2DS2 and KIR2DL2/HLA-C1 combination
has been described as a protective factor against the development of
chronic myeloid leukemia (CML) (Middleton et al., 2009). Patients
with GD are at increased odds of developing CML (OR 3.4) (LandgrenTable 3
Frequencies (%) of C1 and C2 groups in Gaucher disease relative to the absence (17)
and presence (14) of polyclonal/monoclonal bands.
Ligand groups Polyclonal/monoclonal
bands
p-Value OR 95% CI
Absent Present
N % N %
C1C1 2 11.8 5 35.7 0.198 – –
C2C2 1 5.9 8 57.1 0.007 21.3 2.18–208.7
C1C2 14 82.4 1 7.1 b0.001 0.016 0.002–0.179
C1C2: C1 and C2 group heterozygous;
C1 group: HLA-Cw 01, 03, 07 (01–06), 08, 12 (02, 03, 06), 14, 16 (01, 03, 04); C1C1: ho-
mozygous for C1 group;
C2 group: HLA-Cw 02, 04, 05, 06, 0707, 12 (04, 05), 15, 1602, 17, 18; C2C2: homozy-
gous for C2 group.
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sociated with adult persistent immune thrombocytopenia (Nourse et
al., 2012). Two of the three patients in our sample who exhibit persis-
tent thrombocytopenia despite ERT have the KIR2DS2/DL2 genotype
(data not shown); therefore, this variant may mask therapeutic failure.
The main ﬁnding of this study was the association between HLA-C
and the presence of serum protein electrophoresis changes. Patients
with the C2/C2 genotype had an OR of 21.3 for the development of
monoclonal or polyclonal bands. Ninety-four percent of patients
who did not develop gammopathy had at least one C1 allele, whereas
43% of patients who did develop gammopathy had at least one C1 al-
lele. On the basis of these data, the presence of C1 appears to be a pro-
tective factor against the development of gammopathies. There is
substantial interest in explaining why GD patients have a greater fre-
quency of MM. The hypothesis that mutations in the GBA gene may be
a risk factor was not conﬁrmed in a study of 95 patients with MM
(Rosenbloom et al., 2009). The only patient with suspected MM in-
cluded in our sample, who presented with IgG kappa monoclonal
pike in protein electrophoresis (data not shown), was found to be ho-
mozygous for the C2 allele, which leads us to believe that the C2/C2
genotype may be considered a risk factor for the development of
this gammopathy.
This was the ﬁrst study to analyze KIR/HLA variants in GD patients.
Although limited in size, our sample exhibited broad variability of this
gene system, with a variety of genotype proﬁles, and our ﬁndings
suggest a potential association between KIR and HLA genes and GD,
thus corroborating the importance of immune system involvement
in this disorder. Further study of KIR/HLA variants in other patient co-
horts is warranted, as they seem to be a phenotype-modifying factor
in GD.
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